In addition to deep phenotypic assessment, we also directly assessed the functional capacity of T-cells in AML using IFNγ T-cell ELISPOT assays in 5 patients who had available baseline and post-vaccination samples (including the 2 AML-R and 3 AML-NR). The gene discussed is IFNG; the disease is acute myeloid leukemia.